Cell-cycle analyses of stem and progenitor cells after drug challenge
| . | Stem cells, % . | Progenitors, % . | ||
|---|---|---|---|---|
| Normal . | bcCML . | Normal . | bcCML . | |
| Untreated | 19 | 18 | 27 | 29 |
| Ara-C 4 h | 12* | 11* | 12* | 17* |
| Ara-C 20 h | 18 | 23 | 21 | 29 |
| Imatinib | 13 | 14 | 35* | 36* |
| . | Stem cells, % . | Progenitors, % . | ||
|---|---|---|---|---|
| Normal . | bcCML . | Normal . | bcCML . | |
| Untreated | 19 | 18 | 27 | 29 |
| Ara-C 4 h | 12* | 11* | 12* | 17* |
| Ara-C 20 h | 18 | 23 | 21 | 29 |
| Imatinib | 13 | 14 | 35* | 36* |
Percentage of cells in S + G2 phases of cell cycle for indicated populations. Analyses performed in triplicate for each condition, all results within 10% standard deviation.
Percentages with statistically significant increase or decrease relative to untreated controls (P < .05).